Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
(NasdaqGM:ETON), Product is currently under review with the FDA Potential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an […]